Results 71 to 80 of about 9,194,076 (301)

Amplification of HIV-1 Infectious Virus in BL3 Lab

Bio-Protocol, 2012
This method is used for making high titer human immunodeficiency virus type-1 (HIV-1) virus stock for subsequent infection assays. The amplification of T-tropic HIV-1 virus (IIIB strain) uses the CD4+ T cell line H9.
Xin Wang
doaj   +1 more source

Super-resolution microscopy reveals specific recruitment of HIV-1 envelope proteins to viral assembly sites dependent on the envelope C-terminal tail [PDF]

, 2013
The inner structural Gag proteins and the envelope (Env) glycoproteins of human immunodeficiency virus (HIV-1) traffic independently to the plasma membrane, where they assemble the nascent virion. HIV-1 carries a relatively low number of glycoproteins in
Mike Heilemann, Barbara Müller, Walter Muranyi (212637), Malkusch, Sebastian, Müller, Barbara, Hans-Georg Kräusslich (7273), Walter Muranyi, Mike Heilemann (162287), Barbara Müller (212640), Sebastian Malkusch (383895), Muranyi, Walter, Hans-Georg Kräusslich, Kräusslich, Hans-Georg, Sebastian Malkusch, Heilemann, Mike   +14 more
core   +2 more sources

Isolation of a new HIV-2 group in the US

Retrovirology, 2008
Human immunodeficiency virus type 2 (HIV-2) emerged following cross-species transmission of simian immunodeficiency virus (SIV) from sooty mangabeys to humans several decades ago. The epidemic groups of HIV-2 have been established in the human population
Gautam Aarti, Gautam Rajeev, Austin Louise, Shah Urvi, de Lame Valéry, Christian Deanna, Smith Stephen M, Apetrei Cristian, Marx Preston A   +8 more
doaj   +1 more source

Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy [PDF]

, 2001
Background: Patients with human immunodeficiency virus (HIV) infection and a history of Pneumocystis carinii pneumonia are at high risk for relapse if they are not given secondary prophylaxis. Whether secondary prophylaxis against P.
H. Furrer, Uberti-Foppa, C., Pradier, C., Bickel, M, Monforte, A D´Arminio, Bickel, M., M. M. E. Schneider, Uberti-Foppa, C, O. Kirk, Furrer, H, Kirk, O., Schneider, M. M., Kirk, O, Lundgren, Jens Dilling, Ledergerber, B., Mocroft, A., Ledergerber, B, Lundgren, J.D., M. Bickel, P. Reiss, Lundgren, J. D., d'Arminio Monforte, A., Pradier, C, A. d'Arminio Monforte, Lederberger, B., Furrer, H., Reiss, P, Schneider, MM, A. Mocroft, for eight European HIV Cohorts, B. Ledergerber, C. Pradier, J. D. Lundgren, Schneider, M.M.E., Mocroft, A, Reiss, P., C. Uberti Foppa   +36 more
core   +2 more sources

Chicken Pulmonary MicroRNAs Targeting the PB2 (Segment 1) of Avian Influenza Virus

Animal Research and One Health, EarlyView.
The PB2 segment of H5N1 is essential for replication and host adaptation. We screened 200 miRNAs and identified five (gga‐miR‐17‐3p, gga‐miR‐29a‐5p, gga‐miR‐1718, gga‐miR‐16c‐5p, and gga‐miR‐1744‐5p) using thermodynamic stability of heteroduplex, seed sequence complementarity, conservation, and accessibility, offering insights into host antiviral ...
Akanksha Choudhary, Nidhishree N. S, Rakesh Kumar Pundir, Muhasin Asaf V. N, Anamika Mishra, Ashwin Ashok Raut, Megha Agarwal, Amod Kumar   +7 more
wiley   +1 more source

A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction [PDF]

, 2008
Feline immunodeficiency virus (FIV) targets helper T cells by attachment of the envelope glycoprotein (Env) to CD134, a subsequent interaction with CXCR4 then facilitating the process of viral entry.
Margaret J Hosie, Ayman Samman, Willett Brian J, Samman, Ayman, Logan Nicola, Brian J Willett, Samman Ayman, McMonagle, Elizabeth L., Hosie Margaret J, Logan, Nicola, McMonagle Elizabeth L, Nicola Logan, Hosie, Margaret J., Willett, Brian J., Elizabeth L McMonagle   +14 more
core   +1 more source

Autoimmune blistering disorders in the setting of human immunodeficiency virus infection

International Journal of Women's Dermatology, 2018
The interplay between immune dysfunction and human immunodeficiency virus (HIV) is complex. Reports of autoimmune disorders including autoimmune bullous disorders (AIBDs) have been increasing in prevalence in the HIV population since the introduction of ...
M.S. Min, MD, MSci, E. Damstetter, MD, A.Y.Y. Chen, MD   +2 more
doaj   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

Neuropsychiatric profile of a cohort of perinatally infected HIV positive children after one year of antiretroviral medication [PDF]

, 2012
Includes abstract.Includes bibliographical references.The Highly Active Antiretroviral Therapy (HAART) era in the mid-nineties signalled a dramatic change in the long-term outcome of Human Immunodeficiency Virus (HIV).
Nassen, René
core   +1 more source

Chimeric antigen receptor T-cell therapy and bispecific antibodies in the treatment of lymphoma for human immunodeficiency virus-infected patients: A systematic review

SAGE Open Medicine
Background: Chimeric antigen receptor T-cell therapy has emerged as a highly effective treatment for relapsed and refractory lymphomas; however, its application in individuals with human immunodeficiency virus remains underexplored.
Alejandra Viera Plasencia, Jeremy I. Purow, Julia Steger, Alexander Brown-Whalen, Henna Qadri, Nicolas Duque Clavijo, Marco Ruiz-Andia   +6 more
doaj   +1 more source